Duality Advisers’s BeOne Medicines Ltd ONC Stock Holding History

Duality Advisers’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,468	Closed	-$504K	–	732
2021 Q2	$504K	Buy	+1,468	New	+$486K	0.04%	433

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Duality Advisers's ONC Position: Q3 2021 in Review

Duality Advisers sold out of BeOne Medicines Ltd (ONC) in Q3 2021, closing a stake of 1,468 shares — an estimated $504K sold.

Duality Advisers first reported a position in ONC in Q2 2021 and held it in 1 quarter. The position peaked at $504K in Q2 2021. 254 funds tracked by Wall St. Rank hold ONC as of Q3 2021.

Duality Advisers reported no remaining BeOne Medicines Ltd position as of Q3 2021 after selling out during the quarter.
Duality Advisers sold 1,468 BeOne Medicines Ltd shares in Q3 2021, an estimated $504K.
Duality Advisers first reported a position in BeOne Medicines Ltd in Q2 2021 and held it in 1 quarter.
Duality Advisers's BeOne Medicines Ltd position peaked at $504K in Q2 2021.
254 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2021.

Based on Duality Advisers's 13F filing for Q3 2021, filed 8 Nov 2021.